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Because the prevalence of allergic diseases has significantly increased in recent years, understanding 
the causes and mechanisms of these disorders is of high importance, and intense investigations are 
ongoing. Current knowledge pinpoints immune tolerance mechanisms as indispensable for healthy 
immune response to allergens in daily life. It is evident that development and maintenance of allergen-
specific T cell tolerance is of vital importance for a healthy immune response to allergens. Such 
tolerance can be gained spontaneously by dose-dependent exposures to allergens in nature or by 
allergen-specific immunotherapy. Allergen-specific immunotherapy induces regulatory T cells with 
the capacity to secrete interleukin-10 and transforming growth factor-β, limits activation of effector 
cells of allergic inflammation (such as mast cells and basophils), and switches antibody isotype from 
IgE to the noninflammatory type IgG4. Although allergen-specific immunotherapy is the only method 
of tolerance induction in allergic individuals, several factors, such as long duration of treatment, 
compliance problems, and life-threatening side effects, have limited widespread applicability of 
this immunomodulatory treatment. To overcome these limitations, current research focuses on the 
introduction of allergens in more efficient and safer ways. Defining the endotypes and phenotypes of 
allergic diseases might provide the ability to select ideal patients, and novel biomarkers might ensure 
new custom-tailored therapy modalities.
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Introduction
Immune tolerance is essential for maintenance of homeostasis. In the network of 
immune regulation, continuous stimuli-response interactions are in harmony with 
functional tolerance mechanisms. The numerous antigens encountered by the host in 
daily life, especially through mucosal surfaces, challenge the highly reactive immune 
system, but the stimuli normally lead to a healthy unresponsiveness, i.e., tolerance. Such 
unresponsiveness is essential for the well-being of the host. What happens in the state 
of responsiveness, as in intolerance? External antigens, or allergens, can trigger harmful 
hypersensitivity reactions, which might present clinically as allergic rhinitis, asthma, 
atopic dermatitis, food allergy, or anaphylaxis. Similar symptoms can be triggered by 
internal antigens. Intolerance to self-antigens leads to the development of autoimmune 
disorders. Excessive tolerance, however, may lead to invasion by microorganisms or 
parasites, or to development of cancer. Clearly, regulation of tolerance is essential for 
life. The best example of the paramount need for regulation of tolerance is pregnancy, in 
which tolerance to paternal and fetal antigens by the fetus and mother, respectively, is 
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essential until birth. 
Therapeutic induction of tolerance could restore normal 
immunity in conditions such as allergic and autoimmune 
disorders. Allergen-specific immunotherapy (SIT) is one of 
the best models to illustrate tolerance induction by external 
antigens1). Understanding the key steps in allergen-SIT might 
facilitate the development of novel therapeutic approaches for 
autoimmune disorders and cancer2).
Allergic immune response
The allergic immune response is directed against various 
environmental allergens. Clinical manifestations include 
allergic rhino-conjunctivitis, allergic asthma, atopic dermatitis, 
food allergy, and anaphylaxis. It has been proposed that a 
tendency to develop T helper type 2 (Th2) immune response is 
prominent in atopic individuals under the influence of genes 
and microenvironment3). Subsets of immune and inflammatory 
cells interact through cytokines. The key cytokines responsible 
for the allergic response include interleukin (IL) 4, IL-13, and IL-
54). Specific recognition of antigenic determinants (epitopes) of 
allergens by T and B lymphocytes elicits the immune response5). 
The recognition is controlled by highly specialized antigen-
presenting cells located in strategic positions, such as mucosal 
surfaces (gastrointestinal mucosa and airway epithelium) and the 
dermis. Processing and presenting allergenic epitopes to T-helper 
(Th) lymphocytes in the presence of relevant costimulatory 
cytokines, chemokines, signals, vitamins, histamine-adenosine-
like small molecules, and other cells in the micro milieu shape 
the immune response6,7). Especially in the presence of IL-4, naïve 
T cells activated by antigen-presenting cells differentiate into 
Th2 cells. In the presence of IL-4 and IL-13, class-switching 
in B cells promotes the synthesis of IgE antibodies. Allergen-
specific IgE antibodies bind to high-affinity FcεRI receptors that 
are expressed on mast cells and basophils. Re-exposure to the 
sensitizing allergen activates mast cells and basophils to produce 
and release biogenic mediators (histamine, proteases, and newly 
generated lipid-derived mediators, such as leukotrienes and 
cytokines) that are responsible for the symptoms and signs of 
type-1 hypersensitivity allergic reactions. In the late-phase 
response, 6–12 hours after allergen exposure, a cell-driven 
process occurs, whereby eosinophils, neutrophils, basophils, T 
lymphocytes, and macrophages infiltrate and release additional 
inflammatory mediators and cytokines, perpetuating the 
proinflammatory response8,9). A characteristic of this phase is 
the heightened role of IL-5, the cytokine responsible for the 
activation, survival, and tissue recruitment of eosinophils. 
This late-phase response is thought to be responsible for the 
persistent, chronic signs and symptoms of allergic diseases. 
Fig. 1. Initiation of allergy. T helper type 2 (Th2) cells are induced when dendritic cells present peptides of 
allergens to naïve CD4+ T cells when interleukin (IL) 4 is present in the milieu. Th2 cells produce cytokines 
IL-3, IL-4, IL-5, IL-9, and IL-13, which are named Th2-type cytokines. B cells switch to produce IgE and bind 
to specific Fcε receptors on mast cells and basophils. This is known as sensitization. Upon encountering the 
same allergen for a second time, degranulation of mast cells and basophils takes place, leading to immediate 
hypersensitivity. Th2-type cytokines are important survival signals for mast cells, basophils, and eosinophils.  
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Continued exposure to allergen often establishes a state of 
chronicity10) (Fig. 1).
Allergic immune response in clinical perspectives
The allergic immune response and atopic status of children 
are active areas of investigation because childhood provides a 
period in which to study the developmental steps and natural 
history of allergic disorders. According to the widely known 
atopic march concept, exposition of atopic individuals to new 
antigens (possible allergens) during weaning from breast-
feeding may induce clinical symptoms such as atopic dermatitis 
or gastrointestinal intolerability. Over time, tolerance to most 
food allergens develops as part of the maturing immune sys-
tem. Thereafter, especially in the very early nursery years, 
atopic children begin to develop immune hypersensitivity to 
aeroallergens. Such children generally suffer from allergic 
rhino-sinusitis and/or asthma symptoms and require long 
periods of treatment regimens, which are followed by decreased 
quality of life11). Although allergen sensitization is known as 
a common cause of these disorders, substandard avoidance 
measures may not resolve the problem. Moreover, conventional 
pharmacotherapy regimens proposed by highly cited guidelines 
may fail to control the disease. To improve understanding of 
the allergic immune response, the multiple factors involved in 
triggering and the different phenotypes and endotypes of allergic 
disorders must be clarified. Future developments in this field 
may lead to novel customized pharmacotherapy options for cure 
of allergy. Several meta-analyses have delineated the impact 
of allergen-SIT on tolerance development. In some periods of 
childhood, the development of allergic disorders along with 
shaping the immune response depends on multifactorial stimuli. 
Such factors include the child’s genes, microenvironment and 
concomitant triggering events, and age. 
Regulatory T cells
Humans react to allergens in various ways. For a healthy 
immune response, unresponsiveness to allergens is of vital 
importance. Immune tolerance to allergens is the formation of 
long-term clinical tolerance toward allergens that is sustained 
by changes in memory-type and allergen-specific T and B cell 
responses and up-regulation of mast cell and basophil activation 
thresholds, with the eventual control of allergy symptoms8,12-14). 
Regulatory T (Treg) cells are a subset of T cells with immune 
regulatory properties. The naturally occurring, thymus-selected 
CD4+CD25+FOXP3+ Treg cells and the inducible type-1, IL-10-
secreting Treg cells (Tr1 cells) are the major subsets of Treg cells. 
Tr1 cells are responsible for maintenance of peripheral tolerance. 
Forkhead box P3 (FoxP3) is the lineage-specific transcription 
factor for CD4+CD25+ Treg cells and has a functional master 
regulator role in the development of multiple subtypes of Treg 
cells15). Various suppressor and regulatory mechanisms have 
roles in the maintenance of immune homeostasis by Treg cells, 
which includes inhibition of the development of allergen-specific 
Th2 and T helper type 1 (Th1) cell responses and the direct or 
indirect suppression of effector cells of allergic inflammation16) 
(Fig. 2). Impaired allergen-specific suppressive function of 
CD4+CD25+ Treg cells has been demonstrated in allergic patients 
relative to nonallergic controls. Circulating CD4+CD25+ Treg cells 
in nonallergic healthy individuals have been shown to suppress 
proliferation of allergen-specific effector cells on exposure to 
allergens to a greater extent than Treg cells from sensitized 
individuals17). 
Induction of allergen-specific peripheral tolerance
Peripheral induction of T cell tolerance by allergen-specific 
regulatory Tr1 cells is vital to healthy immune responses to 
allergens18-20). The overall number of T cell numbers is controlled 
normally by the central tolerance mechanism. However, some 
T cells escape from thymic deletion and peripheral tolerance is 
developed in peripheral lymphoid organs. Peripheral tolerance 
is regulated by factors such as T cell anergy, apoptosis, Treg 
cells, suppressive cytokines, and antigen presenting cells 
(APCs)21). Studies have shown that healthy patients possess 
a peripheral T cell repertoire that recognizes the same T cell 
epitopes of allergens as allergic patients. The precise balance 
between the frequency of allergen-specific Th2 and Tr1 cells 
directed to common environmental allergens defines an allergic 
or a healthy status10). These findings emphasize the important 
contribution of Tr1 cells to the active regulation that is important 
in inducing and maintaining specific unresponsiveness to 
allergens. The unresponsiveness is primarily maintained by IL-
10 and transforming growth factor (TGF)-β, which are produced 
by antigen-specific Treg cells. It has been suggested that both 
naturally occurring FoxP3+ and inducible Tr1 cells contribute 
to the establishment of peripheral T cell tolerance to allergens22). 
Establishment of clinical tolerance in humans is associated 
with the loss of IL-4-producing T cells and an increase of IL-
10-producing antigen-specific Treg cells23). In addition to IL-10, 
Treg cells produce TGF-β, a suppressive cytokine. Additionally, 
there are changes in production of cytokines by antigen-specific 
T cells. A reduction in IL-4 production and an increase in IL-
10 production are significant23). IL-10 and related cytokines, IL-
19, IL-20, IL-22, IL-24, and IL-26, participate in T cell-mediated 
diseases by regulation of T cell cytokine profiles24). In addition to 
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IL-10, expressions of costimulatory molecules CD80, CD86, and 
programmed cell death ligand 1 are reduced, which may down-
modulate T cell immune responses25). Treg cells also strongly 
express CTLA-4, which inhibits T cell activation, in contrast 
to CD2826). TGF-β is an important suppressive cytokine that is 
essential for the maintenance of immunologic self-tolerance27). 
Conversion of naïve CD4+ T cells to Treg cells requires induction 
of FoxP3 by TGF-β. The conversion is required for both 
expansion in number and suppressive capacity of Treg cells28,29). 
Impact of allergen presentation
Dendritic cells (DCs) are important members of the immune 
system and play a pivotal role in the orchestration of immune 
responses by linking innate and adaptive immunity30). Circulating 
DCs in humans can be divided into two main groups: myeloid 
dendritic cells (mDC) and plasmacytoid dendritic cells (pDC), 
both of which are equipped with different repertoires of Toll-
like receptors (TLRs)31,32). pDCs express TLR7 and TLR9, whereas 
mDCs express TLR833). Loss of allergen-specific peripheral T cell 
tolerance in response to TLR8-ligand (L) stimulation but not to 
TLR7L or TLR9L stimulation underlines the contribution of pDCs 
to tolerance induction34). Such important roles for pDCs had 
been reported in the induction and maintenance of peripheral 
tolerance to food and inhalant allergens in human tonsils35). In 
addition to DCs, TLRs also regulate B-cell responses. Stimulation 
of B cells with ligands for TLR3, TLR7, and TLR9 induce the 
generation of memory B-cells and the production of IgG1, IgA, 
and IgG4. Mammalian telomeric oligodeoxynucleotide (ODN) 
suppresses activation of B cells, production of antibodies and 
generation of memory cells. All of these findings support roles of 
TLR-triggering in the regulation of allergic responses36). 
The other players of immunity
Subsets of antigen-presenting cells, such as DCs and B-cells, 
that are capable of producing IL-10 were shown to contribute to 
the suppressive effects of IL-1037,38). Natural killer (NK) cells are 
important factors in innate immunity. Circulating NK cells retain 
effector subsets, such as NK1 and NK2, with distinct cytokine 
•
•

Fig. 2. Mechanisms of tolerance to allergens. Allergen specific immunotherapy and high-dose encounters with 
allergens induce Treg cells, which leads to peripheral tolerance. The effector cells of allergic inflammation 
are regulated by regulatory and suppressive functions of Treg cells in various ways. Treg cells suppress t 
helper type 2 (Th2)  cells and their cytokine production (interleukin [IL] 3, IL-4, IL-5, IL-9, and IL-13), which 
are indispensable, both for the differentiation, survival, and activity of mast cells, basophils, eosinophils, 
and mucus producing cells and for tissue homing of Th2 cells. IL-10 and transforming growth factor (TGF)-β 
suppress IgE production while inducing IgG4, which is a noninflammatory immunoglobulin isotype.
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profiles, similar to Th1 and Th2-cells. These cells are claimed to 
display different inflammatory properties39). Recent studies have 
revealed a subset of NK cells that produce IL-10 and suppress 
allergen-specific T cell responses40). Recently, a subset of B 
cells that are capable of producing IL-10, expressing IgG4, and 
suppressing allergen-specific CD4+ T cell proliferation has been 
demonstrated and named as B-regulatory 1 cells41). Suppression 
by IL-10 occurs in various ways. T cells are suppressed by 
blocking CD2, CD28, and inducible costimulator (ICOS) costi-
mulatory signals by IL-10. The mechanism employs the Src 
homology 2 domain-containing tyrosine phosphatase (SHP-1) 
which rapidly binds to CD28 and ICOS and de-phosphorylates 
them42,43). IL-10 also inhibits activated monocytes and 
macrophages which is revealed by suppression of costimulatory 
molecules on these cells and by down-regulation of MHC class 
II molecules and down-regulation of antigen-presenting cell 
capacity44,45). It has been shown that expression of the SOCS3 
gene was induced by IL-10, possibly due to the inhibition of 
interferon (IFN)-γ-induced tyrosine phosphorylation of signal 
transducer and activator 146). 
Antibody responses during tolerance development
Induction of peripheral tolerance also induces changes in 
antibody isotypes. Serum allergen-specific IgE levels decrease 
gradually, while allergen-specific IgG4 blocking antibodies 
increase during allergen-SIT9,47,48). In contrast to T cells, B cell 
responses to antigenic stimuli are not fully suppressed. They 
switch to produce IgG4 instead of IgE47). IL-10 contributes to 
the regulation of specific antibody isotypes to move toward a 
noninflammatory phenotype49,50). Important blocking effects 
of IgG4 are maintained by its ability to compete with the Fcε 
receptors on IgE for binding antigens. Because IgE is expressed 
on the surface of mast cells and basophils, the competition 
for binding antigens limits effector cell activation and degra-
nulation51). In addition, blocking antibodies can prevent the 
activation of CD4+ cells by inhibiting CD23-mediated IgE-
facilitated presentation of antigens52).
Immune regulatory role of histamine
Histamine has functional roles in immune regulation through 
four distinct histamine receptors (HR). Among these, HR2, which 
is relatively highly expressed on Th2 cells, induces Treg cells and 
supports development of antigen-specific peripheral tolerance. 
Up-regulation of HR2 increases IL-10 levels, suppresses T cell 
stimulation, and enhances the suppressive action of TGF-β on T 
cells. HR4 modulates migration of eosinophils and recruitment 
of mast cells and is involved in DC activation and T cell 
differentiation7,53).
Conventional routes for immunotherapy; 
subcutaneous and sublingual ways
Recent studies have extensively investigated mechanisms 
of immune tolerance induction. The therapeutic induction of 
immune tolerance through either allergen-SIT or spontaneous 
induction, such as in beekeepers or cat owners, is highly 
important to the field. Complex mechanisms have been proposed 
to explain establishment of peripheral tolerance50,54,55). SIT is 
known to be the only available curative treatment of allergic 
diseases. Peripheral tolerance induction by the generation of 
allergen-specific Treg cells, which have suppressive proliferative 
and cytokine response capabilities, is the consequence of 
SIT19,49). Subcutaneous immunotherapy and sublingual immu-
notherapy (SLIT) routes are primary administrative routes for 
immunotherapy. In addition to bee-venom injection immu-
notherapy, both routes are successfully used for pediatric 
and adult allergic rhinitis and asthma patients56,57). Increased 
production of IFN-γ following SLIT has been correlated with the 
success of immunotherapy58).
Peripheral tolerance can also be established as a consequence 
of natural, high-dose allergen exposure. In healthy nonallergic 
beekeepers and cat owners55,59), Treg cells specific for the 
relevant major allergens become the major T cell subset of these 
individuals by utilizing multiple suppressive mechanisms, such 
as secreted cytokines IL-10 and TGF-β and surface molecules 
CTLA-4 and PD-1. High-dose exposure models such as bee-
keepers enhance our understanding of the nature of Treg 
responses in immune tolerance induction22).
Novel therapeutic approaches of allergen-SIT
The side effects and long duration of treatment in allergen-
SIT are undeniable negative impacts on the use of this strategic 
treatment. Improvements in ease of administration and safety 
may expand application to indications such as atopic dermatitis, 
food allergies, and large local bee sting reactions. Promising 
developments in the field of allergen-SIT include modified 
allergens and new routes of administration. Knowledge of the 
influence of IgE-facilitated antigen presentation in allergen-
specific Th2 responses have led to investigation of methods 
to generate non–IgE-binding allergens60). Utilizing genetic 
engineering methods, two major bee venom allergens, 
phospholipase A2 and hyaluronidase, have been fused in a 
manner that removes B-cell epitopes in order to prevent IgE 
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cross-linking and preserves T cell epitopes due to conformational 
changes of the antibody. The novel fusion protein Api M 
(1/2) abolishes IgE reactivity, reduces basophil degranulation, 
and produces type-1 skin reactivity61). In addition to allergen 
modification, routes of administration are also under intense 
investigation. A novel method to introduce the allergen in a 
more efficient way was recently described. Modular antigen 
translocating (MAT) molecules present the allergen to the 
major histocompatibility class-II pathway intracellularly, which 
enhances antigen presentation. The rapid translocation of the 
MAT-fused allergens in the cytoplasm provides a significant 
advantage. Intracytoplasmic accumulation of the MAT–fused 
allergens can induce stronger proliferation responses to the 
corresponding allergens, even at 10–100 times lower con-
centrations. Cytokine responses in PBMC cultures revealed 
marked increases in IL-10 and IFN-γ secretion and decreases in 
IL-4 and IL-5 responses compared with those induced by the 
corresponding recombinant allergen62).
As a promising route, intralymphatic allergen administration 
under ultrasound guidance can induce tolerance with three 
injections, which provides a significant advantage over classical 
multiple subcutaneous injections. Recently, a randomized 
double-blind safety and efficacy study of intralymphatic 
immunotherapy (ILIT) with the recombinant major cat dander 
allergen Fel d 1-MAT molecule was reported. The increase in 
nasal reactivity to the allergen in the ILIT group was pronounced 
compared with the placebo group. In addition, it was shown 
that in the ILIT group, T regulatory cell response was induced 
along with an IL-10 response and increased cat dander-specific 
IgG4 levels63). In another double-blind, placebo-controlled study, 
clinical improvement in nasal allergy symptoms was reported 
in patients with allergic rhinitis who had been treated with three 
intralymphatic injections of birch or grass pollen64).
Similarly, epicutaneous immunotherapy (EPIT) is another 
novel approach in which highly immunogenic skin is the target. 
Although the first successful intervention was in a horse dander 
allergic asthmatic patient in 192165), this route has recently 
regained attention. In a recent placebo-controlled, double-blind 
study, the safety and efficacy of EPIT in grass pollen allergic 
rhinitis patients was shown in a dose-dependent manner after 
only six patches66). In another prospective double-blind trial in 
grass pollen allergic children, transcutaneous administration of 
the allergens was shown to be effective in reducing symptoms 
and the use of antihistamines67). Progress in EPIT is promising 
because this method can be a noninvasive alternative to 
immunotherapy in patients with injection-phobia, especially in 
children. 
Loss of peripheral tolerance due to inflammation 
Allergen-specific tolerance is maintained long-term, once 
established. However, the observation of allergic exacerbations 
followed by infections, especially viral infections, has triggered 
studies to investigate the breakage of peripheral tolerance. 
Recent findings revealed that activation of innate immunity by 
specific activators condition specific adaptive immune responses 
to allergens. IL-1β and IL-6 cytokines, with proinflammatory 
properties, and the triggering of TLR4 and TLR8, which recognize 
microbial particles as danger signals, have been shown to lead to 
proliferation of allergen-specific CD4+ T cells in peripheral blood 
of normally unresponsive individuals by various pathways, 
such as forming an inflammatory milieu, potentiating mDCs, 
or rendering T cells unresponsive to Treg suppression34). These 
findings may shed light on how healthy humans develop 
allergic diseases upon encountering microbes or inflammatory 
conditions.
Future perspectives 
Allergen-SIT remains to be the major procedure for long-
term management of allergic disorders. Short falls in strict 
allergen-avoidance measures and failures of sustained clinical 
responses to pharmacotherapies increase the demand for more 
efficient and safer allergen immunotherapy regimens. With 
increasing understanding of the roles of cytokines, chemokines, 
pathways, networks, and cellular interactions, novel modulated 
administration routes are being tested and allergens are being 
developed for more successful immunotherapy regimens. 
However, the new immunotherapy regimens show variable 
clinical responses in allergic individuals. This might be due 
to different endotypes and phenotypes of allergic diseases. 
Discovery of biomarkers to identify these endotypes and 
phenotypes may provide optimum patient selection for relevant 
immunotherapy regimen. Definition of these phenotypes and 
endotypes will enable selection of the best patient for more 
efficient treatment68). The field of allergen-SIT will expand 
with answers to the key questions: “In which patient?”, “Which 
route?”, “Which allergen?”, and “What would be the duration for 
immunotherapy?” Therefore, the importance of establishing data 
to describe the differences between endotypes and phenotypes is 
crucial. Mechanistic studies designed to improve understanding 
of diseases and risk factors and to lead to improved diagnosis 
and therapy should be performed69). Characterization and 
increased understanding of the underlying disease mechanisms 
in allergic diseases might require the use of individualized 
combined applications of immune response modifiers with 
allergen-SIT.
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